Slingshot members are tracking this event:
Celgene (CELG) Phase III data readout of RELEVANCE trial testing Revlimid in previously untreated follicular lymphoma expected by end of 2017
Slingshot Insights Explained
Dec 21, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Phase 3 Results, Relevance, Indolent Non-hodgkin Lymphoma, Revlimid